Pregnancy: No evidence of risk in humans.
Lactation: Contraindicated or not recommended.
Precautions: Exclude malignant disease before and during treatment. Impaired renal function. Monitor patients on long term therapy.
Inj/Tab: For the prophylaxis of stress ulcer syndrome: Duodenal ulcer, benign gastric ulcer, recurrent and stomal ulceration, reflux oesophagitis, Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas, and other conditions where reduction of gastric acid secretion is likely to be beneficial.
Susp: Treatment of acute gastritis which can manifest as heartburn, epigastric pain, hyperacidity, dyspepsia or acute aggravation of chronic gastritis.
TABLET: Active duodenal ulcer: Adults: Single dose of 800 mg at bed time or 400 mg at breakfast and 400 mg at bed time, or 200 mg three times a day with meals and 400 mg at bedtime.
Reflux oesophagitis: Adults: 400 mg four times a day with meals and at bedtime for upto 12 weeks is indicated.
Zollinger-Ellison syndrome and other cases of high gastric secretion: Adults: 200 mg 3 times a day with meals and 400 mg at bedtime.
Acid related dyspepsia: Adults: 200 mg 4 times a
IV: May be administered as a slow IV push or preferably as an IV intermittent or IV continuous infusion. Administer each 300 mg (or fraction there of) over a minimum of 5 min when giving IV push. Give intermittent infusion over 15-30 min for each 300 mg dose. Intermittent infusions are administered over 15-30 min at a final concentration not to exceed 6 mg/ mL; for patients with an active bleed, preferred method of administration is continuous infusion.
Oral anticoagulants, phenytoin, theophylline, IV lignocaine.
Diarrhoea, dizziness, rash, tiredness. Gynaecomastia, occasional reversible liver damage, confusion. Very rarely interstitial nephritis, acute pancreatitis, thrombocytopenia, leucopenia, pancytopenia, aplastic anaemia, fever, headache, myalgia, arthralgia, sinus bradycardia, tachycardia, heart block, anaphylaxis, hallucinations, depression.